Regeneron

Regeneron plots $800M New York production push—along with 1,500 new jobs
Regeneron plots $800M New York production push—along with 1,500 new jobs
Fierce Pharma
Regeneron
drug manufacturing
New York
Flag link:
Regeneron drug proves effective in genetic form of high cholesterol
Regeneron drug proves effective in genetic form of high cholesterol
Stat
Regeneron
Homozygous Familial Hypercholesterolemia
evinacumab
Flag link:
Regeneron gets FDA approval for Eylea injection prefilled syringe
Regeneron gets FDA approval for Eylea injection prefilled syringe
Ophthalmology Times
Regeneron
Eylea
FDA
Flag link:
Regeneron's Ebola treatment proves superior to rival in trial
Regeneron's Ebola treatment proves superior to rival in trial
Yahoo/Reuters
Regeneron
Ebola
Mapp Biopharmaceutical
REGN-EB3
Flag link:
Dupixent brings long-awaited profits to Sanofi, Regeneron partnership
Dupixent brings long-awaited profits to Sanofi, Regeneron partnership
BioPharma Dive
Sanofi
Regeneron
Dupixent
Flag link:
These 5 Firms Could Buy Celgene's Otezla Ahead Of The Bristol Merger
These 5 Firms Could Buy Celgene's Otezla Ahead Of The Bristol Merger
Investors Business Daily
Bristol-Myers Squibb
Celgene
M&A
Otezla
Gilead Sciences
Amgen
Regeneron
Eli Lilly
JNJ
Flag link:
German court blocks sale of Sanofi, Regeneron cholesterol drug
German court blocks sale of Sanofi, Regeneron cholesterol drug
Biopharma Dive
patents
Amgen
Sanofi
Regeneron
Germany
Praluent
Repatha
Flag link:
Sanofi and Regeneron's Dupixent scores 3rd FDA approval in sinusitis with nasal polyps
Sanofi and Regeneron's Dupixent scores 3rd FDA approval in sinusitis with nasal polyps
Fierce Pharma
Sanofi
Regeneron
Dupixent
rhinosinusitis
nasal polyps
FDA
Flag link:
FDA Action Alert: Regeneron, Sanofi, Celgene
FDA Action Alert: Regeneron, Sanofi, Celgene
BioSpace
FDA
drug approvals
Acer Therapeutics
Edsivo
Regeneron
Sanofi
Dupixent
Celgene
Revlimid
Alexion
Soliris
Dova Pharmaceuticals
Doptelet
Nabriva Therapeutics
Contepo
Retrophin
Thiola
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
Yahoo/Benzinga
Merck
Keytruda
Melinta Therapeutics
Amag Pharmaceuticals
Palatin
Acer Therapeutics
Sanofi
Regeneron
Alexion
Pfizer
Roche
Navidea Biopharmaceuticals
Ascendis Pharma
Scholar Rock
Adaptive Biotechnologies
BridgeBio
IPOs
G Medical Innovations
Karuna
Morphic Therapeutics
Flag link:
Rivals’ disappointing results in asthma trial drag down shares of Anaptys Bio
Rivals’ disappointing results in asthma trial drag down shares of Anaptys Bio
Stat
Sanofi
Regeneron
IL-33
asthma
monoclonal antibodies
REGN3500
AnaptysBio
Dupixent
Flag link:
Will The Introduction Of A Third Potent Cholesterol Lowering Drug Expand or Shrink The Market?
Will The Introduction Of A Third Potent Cholesterol Lowering Drug Expand or Shrink The Market?
Forbes
The Medicines Company
Amgen
Sanofi
Regeneron
inclisiran
PCSK9 inhibitors
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts
Yahoo/Benzinga
ADA
Merck
Keytruda
NGM Biopharmaceuticals
NGM313/MK-3655
Corbus Pharmaceuticals
Nektar
Galapagos
Kezar Life Sciences
Kura Oncology
Bluebird Bio
BeiGene
Global Blood Therapeutics
Blueprint Medicines
Regeneron
Arqule
Sunesis
Sutro BioPharma
Incyte
Geron
Forty Seven
Flag link:
ASCO Soundbites, vol. 3: Real-time approvals, Pfizer's second rodeo and 'the busiest ASCO ever'
ASCO Soundbites, vol. 3: Real-time approvals, Pfizer's second rodeo and 'the busiest ASCO ever'
Fierce Pharma
ASCO 2019
Merck
Keytruda
FDA
Pfizer
AstraZeneca
Regeneron
Libtayo
Venclexta
Gazyva
Flag link:
Mark Your Calendar For These June PDUFA Dates
Mark Your Calendar For These June PDUFA Dates
Yahoo/Benzinga
FDA
Merck
Zerbaxa
XERIS
Gvoke HypoPen
Keytruda
Amag Pharmaceuticals
Palatin
Vyleesi
Acer Therapeutics
Edsivo
Sanofi
Regeneron
Dupixent
Alexion
Soliris
Retrophin
Thiola
Allergan
Botox
Flag link:
Go or no go? Merck, Regeneron and Alexion await US expansion
Go or no go? Merck, Regeneron and Alexion await US expansion
EP Vantage
Merck
Keytruda
Sanofi
Regeneron
Dupixent
Alexion
Soliris
FDA
Dova Pharmaceuticals
Retrophin
Flag link:
FDA approves Regeneron’s Eylea for diabetic retinopathy
FDA approves Regeneron’s Eylea for diabetic retinopathy
Pharmaforum
Regeneron
Eylea
diabetic retinopathy
FDA
Bayer
Flag link:
Regeneron’s star bispecific is linked to 2 deaths in a small study — which was no help for its Q1 call
Regeneron’s star bispecific is linked to 2 deaths in a small study — which was no help for its Q1 call
Endpoints
Regeneron
REGN1979
bispecific antibodies
Flag link:
Regeneron bags Calixar tech to support antibody discovery effort
Regeneron bags Calixar tech to support antibody discovery effort
Fierce Biotech
Regeneron
Calixar
antibodies
antibody discovery
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
Yahoo/Benzinga
Regeneron
Sanofi
Praluent
FDA
Heron Therapeutics
HTX-011
Nabiva
Orchard Therapeutics
Akari Therapeutics
Aldeyra Therapeutics
BioTime
Audentes Therapeutics
Adaptimmune
GW Pharma
Ionis
Biogen
Ovid Therapeutics
TransMedics
IPOs
Trevi Therapeutics
Flag link:

Pages